Confluence Life Sciences, Inc., a St. Louis, MO-based biotechnology company, has raised $4m in Series A venture capital funding.
The round was led by DFJ Mercury, and includes conversion of notes by the BioGenerator, Missouri Technology Corporation and the Helix Fund.
Led by Walter Smith, CEO, and Joseph Monahan, Ph.D., Founder and CSO, Confluence focuses on the discovery and development of kinase inhibitors to treat cancer and inflammatory disease. The company now intends to use the capital to advance its product candidates and leverage its proprietary technology platform to discover and develop novel therapeutics.
Confluence also has a wholly owned subsidiary, Confluence Discovery Technologies, Inc. (CDT) which provides high value-added biological assay development and execution for pharmaceutical development on a contract basis.